ChemoCentryx Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
133,313.00
73,357.00
71,278.00
117,764.00
127,291.00
176,984
Total Accounts Receivable
393.00
-
-
30,205.00
51,090.00
2,058
Other Current Assets
596.00
972.00
757.00
722.00
1,449.00
2,342
Total Current Assets
134,302.00
74,329.00
72,035.00
148,691.00
179,830.00
181,384
Net Property, Plant & Equipment
1,399.00
1,208.00
949.00
905.00
1,210.00
1,536
Total Investments and Advances
16,561.00
41,263.00
5,011.00
5,997.00
7,929.00
-
Long-Term Note Receivable
16.00
16.00
16.00
16.00
16.00
16
Other Assets
160.00
181.00
160.00
279.00
359.00
390
Total Assets
152,438.00
116,997.00
78,171.00
155,888.00
189,344.00
183,326
ST Debt & Current Portion LT Debt
314.00
-
-
-
-
Accounts Payable
909.00
748.00
-
671.00
1,400.00
Other Current Liabilities
5,649.00
7,442.00
5,494.00
37,664.00
31,537.00
Total Current Liabilities
6,872.00
8,190.00
5,494.00
38,335.00
32,937.00
Long-Term Debt
16.00
-
-
-
4,676.00
Other Liabilities
226.00
185.00
154.00
67,648.00
72,448.00
Total Liabilities
7,114.00
8,375.00
5,648.00
105,983.00
110,061.00
Common Equity (Total)
145,324.00
108,622.00
72,523.00
49,905.00
79,283.00
Total Shareholders' Equity
145,324.00
108,622.00
72,523.00
49,905.00
79,283.00
Total Equity
145,324.00
108,622.00
72,523.00
49,905.00
79,283.00
Liabilities & Shareholders' Equity
152,438.00
116,997.00
78,171.00
155,888.00
189,344.00

About ChemoCentryx

View Profile
Address
850 Maude Avenue
Mountain View California 94043
United States
Employees -
Website http://www.chemocentryx.com
Updated 07/08/2019
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.